[["patients with hypothyroidism", "are at a higher risk for", "coronary vascular disease"], ["patients with diabetes and related vascular complications", "have an increased incidence of", "low thyroid function"], ["thyroid hormones (THs)", "may be", "key regulators of a healthy vasculature"], ["potential undesirable side effects", "hinder", "the use of THs in treatment of vascular disorders"], ["TH analogs such as 3,5-diiodothyropropionic acid (DITPA)", "may provide", "a safer treatment option"], ["the relative potency of DITPA", "is poorly understood regarding", "vascular growth, cardiac function, and metabolism"], ["the vascular growth-promoting effects of DITPA", "can be obtained with", "a minimum effect on cardiac function"], ["thyroidectomized Sprague-Dawley rats", "were given", "slow-release pellets with either thyroxine (T4) or DITPA"], ["high-dose T4", "prevented", "arteriolar loss and the development of hypothyroidism"], ["low-dose T4", "partially prevented", "the reduction in cardiac function"], ["low-dose T4", "had minimal effects on", "arteriolar loss"], ["DITPA treatment", "prevented", "myocardial arteriolar loss"], ["DITPA treatment", "did not prevent", "the progression of hypothyroid-induced changes in cardiac function"], ["the results", "suggested that", "DITPA can promote a healthy vasculature independently from thyroid-related metabolic effects"], ["drugs in this class", "may provide", "new therapeutic options for patients with vascular disease"]]